Ok, so just safety results, efficacy analyses stil
Post# of 148278
(Total Views: 1022)
Posted On: 07/21/2020 6:11:39 AM
Ok, so just safety results, efficacy analyses still to be completed; though the twofold incidence of SAEs in the placebo arm might gives us an idea of how leronlimab performed:
"39% of Patients in Placebo Arm Had SAEs as Compared to Only 14% of Patients in Leronlimab Arm Had SAEs, Which Were Unrelated to Leronlimab. The Efficacy Portion of the Trial Will be Announced Along With a Full Report as Soon as Statistical Analyses are Completed
Evaluation of safety data indicates the following:
Leronlimab: 5 patients out of 56 (about 9%) reported serious adverse events, none were related to leronlimab
Placebo: 6 patients out of 28 (about 21%) reported serious adverse events".
"39% of Patients in Placebo Arm Had SAEs as Compared to Only 14% of Patients in Leronlimab Arm Had SAEs, Which Were Unrelated to Leronlimab. The Efficacy Portion of the Trial Will be Announced Along With a Full Report as Soon as Statistical Analyses are Completed
Evaluation of safety data indicates the following:
Leronlimab: 5 patients out of 56 (about 9%) reported serious adverse events, none were related to leronlimab
Placebo: 6 patients out of 28 (about 21%) reported serious adverse events".
(3)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼